Abbott IVD manufacturing facility reinspection by FDA expected in next few weeks.
This article was originally published in The Gray Sheet
ABBOTT REINSPECTION BY FDA TO ADDRESS IVD MANUFACTURING DEFICIENCIES is expected to take place in the next few weeks, according to the firm. The reinspection of the company's Abbott Park, Illinois in vitro diagnostic production facilities is intended to verify that Abbott has completed corrective actions taken in response to violations of good manufacturing practices found by FDA during audits in 1993 and 1994. The upcoming inspection will be conducted jointly by FDA's Chicago District Office and centers for devices and biologics.
You may also be interested in...
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.
A report from the US FDA says the agency will focus on updating its premarket submission portal, training staff and taking additional steps to start taking in applications for ASCA pilot participant sponsors.
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.